Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer

1 Dec 2016

Abstract excerpt

Targeted inhibitors of the human epidermal growth factor receptor 2 (HER2), such as trastuzumab and lapatinib, are among the first examples of molecularly targeted cancer therapy and have proven largely effective for the treatment of HER2-positive breast cancers. However, approximately half of those patients either do not respond to these therapies or develop secondary resistance. Although a few signaling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27903634
DOI: 10.1074/jbc.m116.754960

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerPMID 27903634Read ↗

Resistance to Anti-HER2 Therapies in Breast CancerSemantic proximity Read ↗

Mechanisms of lapatinib resistance in HER2-driven breast cancer.Semantic proximity Read ↗

Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast CancerSemantic proximity Read ↗

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitorsSemantic proximity Read ↗

JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted TherapiesSemantic proximity Read ↗

Mechanisms of resistance to HER2 target therapy.Semantic proximity Read ↗

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.Semantic proximity Read ↗

Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast CancerSemantic proximity Read ↗

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.Semantic proximity Read ↗

Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancerSemantic proximity Read ↗

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment responseSemantic proximity Read ↗

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.